Australia's Rhythm Biosciences set for best day in four months on commercialisation of cancer test
12/12/2025 03:08
** Shares of Australia's Rhythm Biosciences RHY.AX jump 38.6% to A$0.115, set for best day since August 6 if gains hold ** Stock at highest since October 15 ** Cancer diagnostics tech firm commences commercialisation of its flagship blood-based colorectal cancer test - ColoSTAT ** YTD shares up 32.2% (Reporting by Shruti Agarwal in Bengaluru) ((Shruti.Agarwal@thomsonreuters.com))
Recent news on Rhythm Biosciences
See all newsBrief: Rhythm Biosciences Says Gavin Fox-Smith Resigns As Chair
Brief: Rhythm Biosciences Announces Appointment Of Non-Executive Directors
Australia's Rhythm Biosciences rises on accelerating commercialisation of cancer test
Brief: Rhythm Biosciences Executes Distribution Agreement For Genetype
Brief: Rhythm Biosciences Seeks Trading Halt